Donmez, S.Pamuk, O. N.Umit, E. G.Top, M. S.2024-06-122024-06-1220120392-856Xhttps://hdl.handle.net/20.500.14551/21084Objective. In this study we evaluated the frequency of autoimmune rheunzatic disease associated major symptoms in fibromyalgia (FM) patients, and the association between their presence and anxiety, depression and somatisation. Methods. Two hundred and thirty-two FM, 78 systemic lupus erythematosus (SLE) patients and 70 healthy controls were included. All subjects were questioned face-to-face for the presence of autoimmune rheumatic disease-associated symptoms and antinuclear antibody (ANA) was determined. All FM patients were questioned for the severity of pain and symptoms of FM by using a visual analogue scale. In addition, all subjects were interrogated for anxiety, depression, somatic symptoms and neuropathic pain by using different validated questionnaires. Results. FM patients had significantly higher frequency of photosensitivity (27.6% vs. 11.4%) and Raynaud phenomenon (22% vs. 10%) when compared to controls (p-values, 0.005 and 0.026). FM patients had significantly lower frequencies of photosensitivity, oral ulcers, xerostomia, and xerophthalmia than SLE patients (all p-values <0.001). ANA positivity was 11.8% in FM patients and 7.1% in healthy controls. ANA-positive and negative FM patients had similar frequencies of autoimmune rheumatic disease symptoms. FM patients with photosensitivity had higher anxiety (p=0.002), somatic symptoms (p=0.015) and neuropathic pain (p=0.03) scores than others. FM patients with Raynaud had higher anxiety (p=0.004), depression (p=0.001), somatic symptom (p<0.001) and neuropathic pain scores than others. Conclusion. The presence of which findings in FM seems to be associated with anxiety, depression, and somatisation rather than ANA positivity and disease severity.eninfo:eu-repo/semantics/closedAccessFibromyalgiaSystemic Lupus ErythematosusAnxietyDepressionSomatisationSystemic-Lupus-ErythematosusAntinuclear AntibodiesImpact QuestionnaireNeuropathic SymptomsLeeds AssessmentPain ScaleClassificationMulticenterPrevalenceValidationArticle306S65S69Q2WOS:0003136024000102-s2.0-8487497047723137613Q2